Variable valve lift

Standard Motor Products Continues Growth of VVT Program

Retrieved on: 
Wednesday, June 28, 2023
Odyssey, Variable valve timing, Tacoma, Washington, IATF, Nissan, Catalog, F-150, Toyota Camry, SMP, Vibration, Ford, Ageing, Silverado, Range Rover Evoque, VVT, Toyota, Solenoid, OE, Variable valve lift, Hyundai, Chevrolet, Pathfinder, Magnet, Engineering, Lubrication, RDX, Land Rover, Kits, Hydraulic machinery, Acura, Porsche

NEW YORK, June 28, 2023 /PRNewswire/ -- Standard Motor Products, Inc. (SMP) continues to add to its Variable Valve Timing (VVT) program, which already includes more than 550 part numbers for import and domestic vehicles.

Key Points: 
  • NEW YORK, June 28, 2023 /PRNewswire/ -- Standard Motor Products, Inc. (SMP) continues to add to its Variable Valve Timing (VVT) program, which already includes more than 550 part numbers for import and domestic vehicles.
  • When the OE fails, technicians trust Standard® and Blue Streak® to deliver precision components that integrate with complex VVT systems.
  • The Standard® VVT Program features Sprockets, Solenoids, Oil Control Valves, and Blue Streak® VVT Service Kits, as well as related parts like VVT Spool Filters, Chain Tensioner Kits, Adjuster Magnets and more.
  • All new Standard® and Blue Streak® VVT components are listed in the catalog found at StandardBrand.com , and in electronic catalog providers.

Standard Motor Products Introduces 276 New Part Numbers

Retrieved on: 
Monday, February 27, 2023
Exploration, Acura, Nissan, Lincoln MKX, General Motors, Gasoline, Cadillac, Senior, TLX, ADAS, Marketing, Actuator, Variable valve lift, Ford, Service King Collision Repair, Chevrolet, Ford Super Duty, Heater core, Highlander, SMP, Trailblazer, Sprocket, VVT, Jeep Grand Cherokee, Connector, Subaru, Toyota, Lexus, CT4, Edge, Pathfinder, Advanced driver-assistance system, WRX, STI, Temperature, Volvo, Car rental

NEW YORK, Feb. 27, 2023 /PRNewswire/ -- Standard Motor Products, Inc. (SMP) has introduced 276 new part numbers since the start of the year.

Key Points: 
  • NEW YORK, Feb. 27, 2023 /PRNewswire/ -- Standard Motor Products, Inc. (SMP) has introduced 276 new part numbers since the start of the year.
  • Included in the release is new coverage for 77 product categories, and 43 part numbers for 2022 and 2023 model-year vehicles.
  • Evident in this release is SMP's continued commitment to the hybrid and electric vehicle market through its Standard® and Four Seasons® brands.
  • Standard's Variable Valve Timing (VVT) program has gained several part numbers, including Sprockets for 1.9 million 2021-19 General Motors vehicles.

Standard Motor Products Introduces New Blue Streak Products

Retrieved on: 
Thursday, June 23, 2022
Ignition, Variable valve lift, Catalog, Distributor, General Motors, Blue Streak, Lexus, VVT, Temperature, SMP, View, Multi-pack, Multimedia, Gasoline

NEW YORK, June 23, 2022 /PRNewswire/ -- Standard Motor Products, Inc. (SMP) announces the expansion of its Blue Streak line.

Key Points: 
  • NEW YORK, June 23, 2022 /PRNewswire/ -- Standard Motor Products, Inc. (SMP) announces the expansion of its Blue Streak line.
  • SMP's latest Blue Streak product release includes 23 new part numbers in the Direct Ignition and Variable Valve Timing categories.
  • As part of the expansion, SMP is pleased to introduce new Blue Streak Ignition Coil Multi-Pack Kits.
  • Blue Streak Heavier-Duty Coils are engineered with improvements and upgrades that continue to elevate Blue Streak products above the competition.

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 7, 2021

Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

Key Points: 
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.
  • The Companys portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidaras proprietary Cloudbreak antiviral platform.
  • Cidara is headquartered in San Diego, California.
  • For more information, please visit www.cidara.com .

Cidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary

Retrieved on: 
Wednesday, September 1, 2021
University, Degenerative disease, Fungus, Securities Act of 1933, Achievement, Human Genome Sciences, Abbott Laboratories, Wharton School of the University of Pennsylvania, Microbiology, Employment, Securities Exchange Act of 1934, Therapy, U.S. Securities and Exchange Commission, Wendell Pritchett, University of Mississippi Medical Center, Forward-looking statement, Reliance, Investment, Acceleration, University of Pennsylvania, Doctor of Philosophy, Business administration, Stanford University School of Medicine, CDTX, Biotechnology, MBA, NASDAQ, SAN, Documentation, Gilead Sciences, Security (finance), Standard of care, Private Securities Litigation Reform Act, GLOBE, Georgetown University Law Center, Patient, COVID-19, Reliance Capital, Variable valve lift, Infection, Pharmaceutical industry

We are excited to welcome Preetam and Shane to Cidaras executive team, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

Key Points: 
  • We are excited to welcome Preetam and Shane to Cidaras executive team, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • I am confident that Preetams extensive corporate finance and business development experience and Shanes significant corporate law expertise will be tremendous assets to our Company.
  • During this period, he also acted as a consultant for healthcare-focused private equity firms and hedge funds.
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Retrieved on: 
Tuesday, August 17, 2021
Center for Drug Evaluation and Research, Wastewater treatment, Degenerative disease, Fungus, Candidiasis, Center, Food, Hospital, Securities Act of 1933, Safety, New Drug Application, Securities Exchange Act of 1934, University, Therapy, U.S. Securities and Exchange Commission, Integrity, School, Heart, Respect, Immunodeficiency, Forward-looking statement, Fungemia, Drug Quality and Security Act, CDTX, Nasdaq, Mortality, SAN, Security (finance), Standard of care, Private Securities Litigation Reform Act, Transplant, Medicine, GLOBE, NDA, Caspofungin, Prestige Consumer Healthcare, Patient, Restore, Mycosis, COVID-19, Variable valve lift, Pharmaceutical industry, Medical imaging

SAN DIEGO and CAMBRIDGE, England, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Mundipharma today announced that the companies have completed recruitment of the pivotal Phase 3 ReSTORE trial evaluating the efficacy and safety of rezafungin as a potential first-line treatment for candidemia and invasive candidiasis.

Key Points: 
  • Completion of enrollment of the ReSTORE trial is a tremendous milestone for all of us, most importantly our patients.
  • If approved, rezafungin would be the first new therapy for the treatment of this deadly disease in over a decade.
  • Cidara has partnered with Mundipharma who will be responsible for bringing rezafungin to patients outside theU.S.andJapan.
  • The trial design is similar to Cidaras Phase 2 STRIVE trial ( NCT02734862 ), which met its primary safety and efficacy objectives.

Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 12, 2021
Income, Forward-looking statement, NASDAQ, Infection, Variable valve lift, U.S. Securities and Exchange Commission, Restore, Research, SAN, Congress, Standard of care, Company, European, Fungus, Janssen Pharmaceuticals, Mycology, Securities Act of 1933, Private Securities Litigation Reform Act, COVID-19, Therapy, Partnership, IND, GLOBE, Degenerative disease, Raymond James Financial, Biotechnology, Security (finance), Drug Quality and Security Act, Patient, Conference, Fungemia, Securities Exchange Act of 1934, Janssen, CDTX, Xbox Series X and Series S, Mycosis, Johnson & Johnson, Pharmaceutical industry, Lithium

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the second quarter ended June30, 2021 and provided an update on its corporate activities and product pipeline.

Key Points: 
  • SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the second quarter ended June30, 2021 and provided an update on its corporate activities and product pipeline.
  • This important partnership provides key external validation of the significant potential for our promising Cloudbreak program.
  • We continue to anticipate filing an IND for our lead influenza candidate, CD388, by the end of 2021.
  • Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

Cidara Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Thursday, August 5, 2021
Fungus, Variable valve lift, Standard of care, Degenerative disease, Therapy, Patient, Vaccine

Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

Key Points: 
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.
  • The Companys portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidaras proprietary Cloudbreak antiviral platform.
  • Cidara is headquartered in San Diego, California.
  • For more information, please visit www.cidara.com .